Internal Medicine, Hematology & Oncology · Burbank, CA
NPI
1306862859
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
201 S Buena Vista St Ste 200
Burbank, CA, 91505
Phone (818) 842-8252
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.4M
149,955 services
Medicare patients, 2024
715
Average age 75
Drug cost, 2024
$9.1M
2,952 prescriptions
Company payments, 2025
$319
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Karo K Arzoo was code J9271 (injection, pembrolizumab, 1 mg), 11,700 times for 15 patients. In total Karo K Arzoo billed 149,955 services in 142 codes, and Medicare paid $3.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-11-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,700 | 15 | $44.70 | $523K |
| J0897 Injection, denosumab, 1 mg | Office | 8,520 | 34 | $20.20 | $172K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,150 | 11 | $0.12 | $714 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,880 | 14 | $5.93 | $17K |
| 85025 Blood Count | Office | 2,208 | 575 | $7.60 | $17K |
| 99214 Office E&M - Established | Office | 1,941 | 507 | $102.14 | $198K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,806 | 44 | $0.09 | $162 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,160 | 26 | $0.71 | $829 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 932 | 23 | $0.07 | $67.95 |
| 96375 Injection Administration | Office | 595 | 59 | $13.79 | $8,208 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 426 | 57 | $0.52 | $220 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 342 | 237 | $12.92 | $4,419 |
| 96413 Chemotherapy Administration | Office | 337 | 60 | $114.80 | $39K |
| 99233 Hospital E&M - Subsequent | Facility | 329 | 90 | $96.68 | $32K |
| 99213 Office E&M - Established | Office | 324 | 142 | $72.08 | $23K |
By year: 2022 $2.5M for 118,092 services; 2023 $3.3M for 132,676 services; 2024 $3.4M for 149,955 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,208 | 575 | $7.60 | $17K |
| 36415 Venipuncture Blood Collection | 157 | 107 | $8.65 | $1,358 |
Medicare prescription drug claims, 2024
In 2024, the drug Karo K Arzoo prescribed most often to Medicare patients was Ondansetron Hcl, with 133 prescriptions and refills. In total Karo K Arzoo wrote 2,952 Medicare prescriptions that cost $9.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ondansetron Hcl Generic | 133 | 133 | 48 | $1,653 |
| Letrozole Generic | 123 | 169 | 21 | $1,777 |
| Potassium Chloride Generic | 121 | 187 | 30 | $1,799 |
| Eliquis Apixaban | 113 | 147 | 28 | $84K |
| Anastrozole Generic | 107 | 200 | 27 | $1,171 |
| Xarelto Rivaroxaban | 100 | 118 | 15 | $62K |
| Gabapentin Generic | 98 | 124 | 19 | $1,116 |
| Hydroxyurea Generic | 97 | 147 | 19 | $2,816 |
| Acyclovir Generic | 93 | 122 | 17 | $1,555 |
| Mirtazapine Generic | 76 | 120 | 19 | $962 |
| Kisqali Ribociclib Succinate | 68 | 68 | Under 11 | $1.2M |
| Dexamethasone Generic | 60 | 71 | 15 | $1,514 |
| Levothyroxine Sodium Generic | 53 | 110 | 20 | $351 |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 45 | 45 | Under 11 | $317K |
| Tamoxifen Citrate Generic | 42 | 54 | Under 11 | $881 |
Brand drugs: - claims; generic drugs: 2,090 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Karo K Arzoo $319 ($319 in general payments such as food, travel and fees) from 5 companies. The largest payer was Menarini Silicon Biosystems, Inc. with $147.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.